Claims

1. A composition comprising a first and a second compound, wherein said first compound is ~~an anti-inflammatory compound~~a corticosteroid and said second compound is a compound specifically targeting a *Staphylococcus*~~bacterial cell, preferably a gram positive bacterial cell~~ comprises one or more enzymatic active domains exhibiting target bond specificity, further comprises at least one cell wall binding domain specifically binding the peptidoglycan cell wall, and wherein said second compound is a polypeptide that has at least 80% identity with SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 98 or 100; and/or wherein said cell wall binding domain has at least 80% identity to any of SEQ ID NO: 4, 6 or 8; and/or wherein said one or more enzymatic active domains has at least 80% identity to any of SEQ ID NO: 10, 12, 14, 16, 18, 98 or 100.

2. A composition according to claim 1, wherein the second compound is a polypeptide that has at least 80% identity with SEQ ID NO: 84, that comprises at least one cell wall binding domain that has at least 80% identity to SEQ ID NO: 6, and further comprises one or more enzymatic active domains that have at least 80% identity to SEQ ID NO: 16.

~~2~~3. A kit of parts comprising:

a) a first vial containing a first composition comprising a first compound as defined in claim 1; and,

b) a second vial containing a second composition comprising a second compound as defined in claim 1 or 2; and optionally,

c) instructions for use, wherein the kit is for use in the manufacture of a medicament for preventing, delaying, and/or curing of dermatitis or eczema.~~preferably comprising a dosage regime.~~

4. Use of a kit of parts according to claim 3, wherein the instructions for use comprise a dosage regime.

~~3. Method of treatment comprising the administration of a composition according to claim 1 and/or the sequential or simultaneous administration of a first and second compound of a kit of parts according to claim 2.~~

~~4. A composition according to claim 1 and/or a kit of parts according to claim 2, for use as a medicament.~~

~~5~~4. ~~A~~ Use of a composition ~~and/or a kit of parts~~ according to claim ~~4~~1 or 2~~, for use~~ in the manufacture of a medicament for preventing, delaying and/or curing of dermatitis or eczema.

~~6. A composition, kit of parts and/or method according to any of the preceding claims, wherein said second compound comprises at least one cell wall binding domain specifically binding the peptidoglycan cell wall of said bacterial cell, preferably gram positive bacterial cell.~~

~~7. A composition, kit of parts and/or method according to any of the preceding claims, wherein said second compound comprises one or more enzymatic active domains exhibiting target bond specificity.~~

~~8~~5. ~~A~~ Use of a composition according to claim 4, or use of a kit of parts ~~and/or method~~ according to claim ~~7~~3 or 4, wherein said target bond is an essential bond in a peptidoglycan layer of said bacterial cell, preferably gram positive bacterial cell.

~~9~~6. ~~A composition, kit of parts and/or method~~Use according to claim ~~7 and/or 8~~5, wherein said one or more enzymatic active domains is selected from or is a combination of a domain of the group consisting of a cysteine, histidine dependent amidohydrolases/peptidase domain, an endopeptidase domain, an amidase domain and a glycosylhydrolase domain.

~~10. A composition, kit of parts and/or method according to any of the preceding claims, wherein said bacterial cell, preferably gram positive bacterial cell is a *Staphylococcus*.~~

~~11~~7. ~~A composition, kit of parts and/or method~~Use according to claim 5 or 6~~ 10~~, wherein said cell wall binding domain originates from or is a homologue of a *Staphylococcus* phage endolysin and/or an *S. simulans* lysostaphin and/or an *S. capitis* ALE-1 bacteriocin.

~~12. A composition, kit of parts and/or method according to claims 10 and/or 11, wherein said second compound is a polypeptide that has at least 80% identity with SEQ ID NO: SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 98 or 100;~~

~~and/or said cell wall binding domain has at least 80% identity to any of SEQ ID NO: 4, 6 or 8; and/or wherein said one or more enzymatic active domains has at least 80% identity to any of SEQ ID NO: 10, 12, 14, 16, 18, 98 or 100.~~

~~13. A composition, kit of parts and/or method according to any of the preceding claims, wherein said second compound is a naturally occurring or mutant bacteriophage, a naturally occurring endolysin or a mutant polypeptide.~~

~~14~~8. ~~A composition, kit of parts and/or method~~Use according to any of the claims ~~10-13~~5 to 7, wherein said second compound is a recombinant polypeptide comprising a multiplicity of said one or more enzymatic active domains exhibiting target bond specificity.

~~15. A composition, kit of parts and/or method according to any of the preceding claims, wherein said first compound is selected from the group consisting of a corticosteroid, a calcineurin inhibitor, an immunotherapeutic compound, a recombinant human IFN-gamma, a microbial probiotic, a cytokine modulator, an inflammatory cell recruitment blocker, and a T cell activation inhibitor.~~